During this time of rapid evolution and discovery in Alzheimer’s disease, neuroimaging is expected to play a critical role in clinical practice.
By participating in our expert-led program you will gain valuable insights into the utilization and interpretation of different tracers and biomarkers, enabling earlier detection of Alzheimer’s disease as well as identifying those who would benefit from novel disease-modifying therapies.
Our program at-a-glance
Program Director and Chair Frederik Barkhof is joined by Lyduine Collij, Alexander Drzezga, and Silvia Morbelli.
Discover the latest breakthroughs, connect with leading experts, and discuss the evolving role of PET imaging in the diagnosis and treatment of Alzheimer’s disease.
About this program
Currently, the global rate of undetected dementia is as high as 60%.
Read more
The introduction of pathology-specific disease-modifying therapies has highlighted the important contribution of PET imaging in detecting the early signs of mild cognitive impairment.
With a heterogeneous clinical population, the interpretative process has formidable challenges. The routine application of PET tracers in current clinical settings revolves around subjective visual appraisal and subsequent binary classification of scans.
PET techniques centered around amyloid and tau are being applied in clinical settings, and require the expertise of nuclear medicine and radiology physicians.
As new data emerges on novel PET biomarkers and tracers, our program will disseminate key insights and evidence-led guidance to help advance diagnostic accuracy and disease modification for Alzheimer’s disease.
This independent educational program is designed for global (excl. UK) nuclear medicine physicists and radiologists.
After participating in the program, learners will be able to:
- Explain the critical role of PET imaging in the new era of disease modification of Alzheimer’s disease
- Appraise the utility of current and emerging PET biomarkers in clinical practice
- Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation
This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.
Interactive video OnDemand
Reproduced from our symposium at EANM
Read more
This interactive video from our symposium at EANM will look at key advances within the world of PET imaging for Alzheimer’s disease; including the novel PET biomarkers and tracers, how to integrate and interpret these in daily practice, and how they have been integral to the development and approval of the new disease-modifying therapies.
The Preparing for the new era of neuroimaging for Alzheimer’s disease made available on https://neuroimaging-alzheimers-disease-ime.springermedicine.com/ and organized by Springer Healthcare IME is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®).
Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications
Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 CreditTM will be required to access the AMA website at https://edhub.ama-assn.org/pages/application to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.
For other countries, please contact the relevant national/regional accreditation authority.
eLearning I Pet Pearls
Imaging interpretation with infographic supporting diagnostic investigation
Read more
An interactive perceptual activity to guide and improve the analysis of different PET trace results.
You will be asked to annotate potential abnormalities and receive video feedback from the experts to help build your confidence to accurately detect the early signs of mild cognitive impairment.
The key learning points in this activity will be summarized in a takeaway infographic with practical tips on how to interpret different PET traces.
EJNMMI I Images of the month
Read more
A series of case reports will be published in the official journal of EANM, The European Journal of Nuclear Medicine and Molecular Imaging. Each one will address a key learning point in recognition of the increasingly important role of PET imaging for Alzheimer’s disease.
Image of the month in EJNMMI
Meet the experts
Program Director and Chair
Prof Frederik Barkhof
Amsterdam UMC, Netherlands and University College London, UK
Frederik Barkhof received his MD from VU University, Amsterdam (NL) in 1988 and defended his PhD thesis in 1992, for which he received the Philips Prize for Radiology (1992) and the Lucien Appel Prize for Neuroradiology (1994). Since 2001 he serves as a full Professor in Neuroradiology at the department of Radiology & Nuclear Medicine at VUmc. In 2015 he was appointed as full Professor of Neuroradiology at institutes of Biomedical Engineering and Neurology at UCL in London (UK) to translate novel imaging techniques. In 2018 he received the John Dystel prize by the US National MS Society and the American Academy of Neurology outstanding contributions to research in MS. In 2019, he became a senior fellow of the ISMRM.
Prof Barkhof was the chairman of the Dutch Society of Neuroradiology and the MAGNIMS study group for many years. He is leading the Queen Square MS Centre Trial Unit, involved in analysis of multicentre drug trials. He serves on the Editorial boards of Radiology, Brain, Multiple Sclerosis Journal, Neuroradiology and Neurology. He is a fellow of the Royal College of Radiology.
Prof Barkhof’s research interests focus on white matter disease, dementia, and glioma. He has authored the books Neuroimaging in Dementia, Clinical applications of functional brain MRI and Clinical Neuroradiology – the ESNR textbook.
Disclosures
Frederik Barkhof has received grants and research support from EPSRC, EU-JU (IMI), NIHR-BRC, GE Healthcare, and ADDI, and honoraria/consultant fees from Combinostics, IXICO, Roche, Merck, EISAI, Biogen, and Prothena. He holds shares in Queen Square Analytics Ltd.
Prof Silvia Morbelli
University of Genoa, Italy
Silvia Morbelli is Associate Professor of Nuclear Medicine at the University of Genoa. Since 2007, she has been a Nuclear Medicine physician at IRCCS Ospedale Policlinico San Martino. She obtained a PhD in Applied Neurosciences in 2010. Prof Morbelli has made contributions related to the use of neuroimaging tools as diagnostic and prognostic biomarkers in the earliest and preclinical stages of Neurodegenerative Dementia and Parkinsonian Syndromes. She is especially interested in the use of Molecular Imaging to disclose networks underlying different clinical phenotypes as well as brain reserve in Alzheimer’s and Lewy Body Diseases. She is a member of the Neuroimaging Committee of the European Association of Nuclear Medicine since 2015 (she served as Chair of the Committee from 2020 to 2022).
Disclosures
Silvia Morbelli has received speaker honoraria from Eli-Lilly, Life Molecular Imaging, Novartis and GE Healthcare.
Prof Alexander Drzezga
University Hospital of Cologne, Germany
Alexander Drzezga studied human medicine at the Ludwig Maximilians University and the Technical University of Munich, obtained a license for medical practice, and took up residency at the Department of Nuclear Medicine of the Technical University of Munich.
In 2002 Drzezga specialized in nuclear medicine, and was a Consultant at the Department before becoming Assistant Professor at the Technical University. Since 2012 he has been Professor and Chair of the Department of nuclear medicine at the University Hospital Cologne, and he is currently the chair of the Department of Nuclear Medicine at the University Hospital Cologne and affiliated with the German Center for Neurodegenerative Disorders (DZNE) and the Institute for Neuroscience and Medicine (INM) at the Research Center Juelich. In 2018 he became Director at the INM.
Drzezga’s research focus is on the application of multimodal and molecular imaging procedures to investigate neurodegenerative disorders and their interrelation to the network architecture of the brain. HE is a member of the AMYPAD project and is a Principal Investigator at the AMYPAD site in Cologne, Germany.
Disclosures
Alexander Drzezga has received grant funding and research support from Siemens Healthineers, Sofie, Novartis/AAA, Life Molecular Imaging, and Deutsche Forschungsgesellschaft; and honoraria or consulting fees from GE Healthcare, Biogen, Japan Radiological Society, Novartis, Lilly Deutschland, Peer View Institute for Medical Education Inc., Bayer Vital GmbH, European Research Council, Invicro, and International Atomic Energy Agency.
He holds Stocks, shares or equity in Siemens Healthineers and Lantheus Holding. In addition he has applied for patent for 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1). He is Associate Editor for The Journal of Nuclear Medicine, Nuklearmedizin/NuclearMedicine, and Nuklearmedizinische Hirnbildgebung in “Angewandte Nuklearmedizin”.
Dr Lyduine Collij
Amsterdam UMC location VUmc and Lund University, Netherlands
Lyduine Collij graduated from the VU University Amsterdam in Neuropsychology and Clinical Neurosciences. She did her PhD at the Amsterdam University Medical Center as part of the European AMYPAD consortium, focused on amyloid-PET imaging in Alzheimer’s disease across the continuum. She subsequently did a two year post-doc within the AMYPAD project, leading the disease modeling work-group and providing project management. She is currently doing a postdoc at the BioFINDER group Lund University, supported by the MSCA and AARF grant to investigate disease heterogeneity in the context of clinical trial design.
Disclosures
Lyduine Collij has received research support from GE Healthcare.
